期刊文献+

泌乳素腺瘤药物治疗耐药性的分子机制研究 被引量:2

下载PDF
导出
摘要 泌乳素腺瘤是激素分泌性垂体腺瘤中最常见的一种,药物即多巴胺受体激动剂是首选的治疗方法,其中溴隐亭是代表性药物。泌乳素腺瘤的耐药性是多因素、多机制造成的,其直接原因是多巴胺D2受体数量下降,或受体亚型D2S/D2L的比例下降。而多巴胺D2受体水平下降的原因包括:mRNA交替剪接修饰缺陷、腺苷酸环化酶活性下降及D2R基因调控因子(如NGF水平)的影响等。
出处 《国际神经病学神经外科学杂志》 2007年第3期236-239,共4页 Journal of International Neurology and Neurosurgery
  • 相关文献

参考文献24

  • 1Bolko P,Jaskula M,Wasko R,et al.The assessment of cabergoline efficacy and tolerabihty in patients with pituitary prolactinoma type.Pol Arch Med Wewn,2003,109 (5):489 -495
  • 2Molitch ME.Pharmacologic resistance in pmlactinoma patients.Pituitary,2005,8(1):43-52
  • 3Molitch ME.Dopamine resistance of prolactinomas.Pituitary,2003,6(1):19-27.
  • 4Vangveravong S,McElveen E,Taylor M,et al.Synthesis and characterization of selective dopamine D2 receptor antagonists.Bioorg Med Chem,2006,14(3):815-825.
  • 5Lan H,Durand CJ,Tceler MM,et al.Structural determinants of pharmacological specificity between D1 and D2 dopamine receptors.Mol Pharmacol.2006,69 (1):185-191
  • 6Pellegrini I,Rasolonjanahary R,Gunz G,et al.Resistance to bromocriptine in prolactinomas.J Clin Endocrinol Meta,1989,69(3):500-509.
  • 7Caccavelli L,Cussac D,Pellegrini I,et al.D2 dopaminergic receptors:normal and abnormal transduction mechanisms.Horm Res,1992,38(1-2):78-83
  • 8Caccavelli L,Feron F,Morange I,et al.Decreased expression of the D2 dopamine receptor isoforms in bromocriptineresistant prolactinomas.Neuroendocrinology,1994,60 (3):314-322.
  • 9Barlier A,Pellegrini-Bouiller I,Caccavelli L,et al.Abnormal transduction mechanisms in pituitary adenomas.Horm Res,1997,47(4-6):227-234.
  • 10Renner U,Arzberger T,Pagatto U,et al.Heterogeneous dopamine D2 receptor subtype messenger ribnocleic acid expression in clinical nonfunctioning pituitary adenomas.J Chn Endocrinol Metab,1998,83(4):1368-1375

同被引文献46

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部